US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
US biotech major Amgen rolled out senior executives and a swish presentation in providing an update on two of its drugs in Phase III trials this week. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
German drug discovery company Evotec has entered a technology development partnership with Danish drugmaker Novo Nordisk in cell therapy. 26 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
LEO Pharma has presented late-breaking data on the DELTA FORCE trial for Anzupgo (delgocitinib) cream as a potential treatment for adult patients with moderate to severe chronic hand eczema (CHE). 26 September 2024
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja (leniolisib), from Netherlands-based Pharming. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Shanghai-based Junshi Biosciences has announced that the European Commission has approved Loqtorzi (toripalimab) for two cancer indications. 26 September 2024
Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly-owned and independently operated as a subsidiary of Bayer, has announced a new strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. 25 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing Phase III KarMMa-9 study. 25 September 2024
Amgen yesterday revealed that Tepezza (teprotumumab [genetical recombination]) has been approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) in Japan. 25 September 2024
Eli Lilly's Kisunla has been approved in Japan for early symptomatic Alzheimer's disease, following its US approval in July 2024. Administered via IV infusion, it targets patients with mild cognitive impairment and dementia linked to amyloid pathology. Kisunla aims to slow cognitive and functional decline in AD patients 25 September 2024
The US Food and Drug Administration has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). 13 May 2022
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
For researchers unaffiliated with an academic library, it can be hard to find, organize, and share scientific papers. Can a new tool address this gap? 12 May 2022
Innovation is critical to complete the green and digital transitions and to secure the EU’s open strategic autonomy. This is why a future-proof regulatory framework, which removes barriers to innovation, will allow cutting edge technology products to be developed and launched in Europe. 12 May 2022
The World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the USA’s National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19. 12 May 2022
Russian drug manufacturers and laboratories are faced with serious shortage of excipients, which is mainly due to serious interruptions in their deliveries to the Russian market, reports The Pharma Letter’s local correspondent. 12 May 2022
Switzerland’s EffRx Pharmaceuticals, Slovenia’s Medis, Russia’s Orpharm, Brazil’s OrphanDC, and Dubai-based Vector Pharma, announced today the newly-formed World Orphan Drug Alliance (WODA). 12 May 2022
In line with most analysts’ expectations, Germany’s Merck KGaA has reported group sales of 5.2 billion euros ($5.4 billion) for the first quarter, an increase of 12.2%. 12 May 2022
Investment company eureKARE, which is focused on financing and building biotech companies in the disruptive fields of synthetic biology and the microbiome, has announced the emergence of eureKING. 12 May 2022
Tokyo’s Taiho Pharmaceutical, a business of Japanese drug major Otsuka Pharmaceutical, has agreed to buy part of Cullinan Oncology, thereby regaining rights to a candidate it out-licensed in 2019. 12 May 2022
US pharma major AbbVie yesterday announced positive top-line results from U-ENDURE, its Phase III maintenance study evaluating the JAK inhibitor Rinvoq (upadacitinib) in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy. 12 May 2022
Netherlands-based Qiagen has signed agreements to acquire a 96% majority ownership stake in Blirt SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. 12 May 2022
Belgium’s cell therapy developer Bone Therapeutics (Euronext: BOTHE) today announced it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic. 12 May 2022
Shares in Miami-based Veru were 4% higher at lunchtime Wednesday on the back of some good news from the US Food and Drug Administration (FDA). 11 May 2022
The market for T-cell lymphomas (TCLs) – a rare type of the blood cancer group of non-Hodgkin’s lymphomas – is expected to see strong growth at a 6.4% compound annual growth rate (CAGR) over the next decade in the world’s eight major markets (8MM). 11 May 2022
Japanese ophthalmology specialist Santen Pharmaceutical has received approval of Verkazia (ciclosporin eye drops) from the National Medical Products Administration (NMPA) in China through its Chinese legal entity for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged 4 years and above. 11 May 2022
Gene therapy company Opus Genetics, which is developing treatments for inherited retinal diseases, today announced the appointment of Jennifer Hunt as chief development officer. 11 May 2022
USA-based brain health drug biotech Mind Medicines (MindMed; Nasdaq: MNMD) today released positive top-line data from a Phase II placebo-controlled investigator-initiated clinical trial evaluating LSD in the treatment of anxiety disorders. 11 May 2022